stf-118804 profile

ID Source	ID
PubMed CID	20916937
CHEMBL ID	4303625
SCHEMBL ID	12468873
MeSH ID	M000600924

Synonym
AKOS001906141
S7316
SCHEMBL12468873
CS-4184
DLFCEZOMHBPDGI-UHFFFAOYSA-N ,
4-[5-methyl-4-[(4-methylphenyl)sulfonylmethyl]-1,3-oxazol-2-yl]-n-(pyridin-3-ylmethyl)benzamide
894187-61-2
stf-118804 ,
stf 118804
4-[5-methyl-4-[[(4-methylphenyl)sulfonyl]methyl]-2-oxazolyl]-n-(3-pyridinylmethyl)benzamide
4-(5-methyl-4-(tosylmethyl)oxazol-2-yl)-n-(pyridin-3-ylmethyl)benzamide
AC-32881
HY-12808
4-{5-methyl-4-[(4-methylbenzenesulfonyl)methyl]-1,3-oxazol-2-yl}-n-[(pyridin-3-yl)methyl]benzamide
4-(5-methyl-4-{[(4-methylphenyl)sulfonyl]methyl}-1,3-oxazol-2-yl)-n-(3-pyridinylmethyl)benzamide
J-690382
EX-A666
benzamide, 4-[5-methyl-4-[[(4-methylphenyl)sulfonyl]methyl]-2-oxazolyl]-n-(3-pyridinylmethyl)-
HMS3653C12
stf118804
stf-118804, >=98% (hplc)
mfcd14918065
NCGC00351609-09
SW219872-1
FT-0700399
AS-16511
BCP09741
BRD-K39171998-001-02-9
CCG-269355
CHEMBL4303625
nsc832262
nsc-832262
NCGC00351609-08

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	1.6933	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	10.6840	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	10.6840	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay ID	Title	Year	Journal	Article
AID1623667	Half life in simulated gastric fluid	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623663	Half life in mouse microsomes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623654	Antiproliferative activity against mouse B-ALL BCR-ABL double knockout cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623682	Induction of apoptosis in human SUP-B15 cells assessed as decrease in cell viability at 5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623653	Antiproliferative activity against mouse B-ALL cells expressing wild type BCR-ABL assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623677	Induction of apoptosis in human SUP-B15 cells assessed as decrease in cell viability at 25 uL after 24 hrs by ApoTox-Glo triplex assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623668	Permeability of compound at pH 7.4 by PAMPA	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623680	Cytotoxicity against human MDA-MB-231 cells up to 30 uM after 24 hrs by propidium iodide staining-based fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623664	Intrinsic clearance in mouse microsomes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623699	Induction of apoptosis in human KOPN8 cells assessed as late apoptotic cells level after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 2%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623675	Half life in human plasma	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623669	Apparent permeability of compound form apical to basolateral side in human Caco2 cells	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623691	Cytotoxicity in human SUP-B15 cells assessed as decrease in cell viability after 24 hrs by bis-AAF-RF110 dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623695	Induction of apoptosis in human SUP-B15 cells assessed as late apoptotic cells level after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 13.5%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623665	Half life in human microsomes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623672	Protein binding in mouse plasma	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623655	Antiproliferative activity against human NALM6 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623678	Cytotoxicity against human SUM149 cells at 100 uM after 24 hrs by propidium iodide staining-based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623683	Cell cycle arrest in human KOPN8 cells assessed as accumulation of cells at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis relative to control	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623673	Protein binding in human plasma	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623661	Therapeutic index, ratio of EC50 for human BJ cells to EC50 for mouse B-ALL cells expressing wild type BCR-ABL	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623674	Half life in mouse plasma	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623684	Cell cycle arrest in human KOPN8 cells assessed as accumulation of cells at G1/G0 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis relative to control	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623658	Antiproliferative activity against human SUP-B15 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623685	Cell cycle arrest in human SUP-B15 cells assessed as accumulation of cells at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623694	Induction of apoptosis in human SUP-B15 cells assessed as late apoptotic cells level after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 83%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623692	Induction of apoptosis in mouse B-ALL BCR-ABL double knockout cells assessed as increase in caspase 3/7 activity after 24 hrs by caspase-Glo 3/7 reagent based luminescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623690	Permeability of compound at pH 7.4 assessed as drug retention by PAMPA	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623659	Antiproliferative activity against human MV411 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623660	Antiproliferative activity against human K562 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623693	Cytotoxicity against human MDA-MB-231 cells at 30 uM after 24 hrs by propidium iodide staining-based fluorescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623656	Antiproliferative activity against human UOCB1 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623698	Induction of apoptosis in human KOPN8 cells assessed as late apoptotic cells level after 24 hrs by Annexin V and propidium iodide staining based flow cytometry (Rvb = 96.4%)	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623657	Antiproliferative activity against human KOPN8 assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623686	Cell cycle arrest in human SUP-B15 cells assessed as accumulation of cells at G1/G0 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623676	Induction of apoptosis in human SUP-B15 cells assessed as increase in caspase 3/7 activity after 24 hrs by caspase-Glo 3/7 reagent based luminescence assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623688	Cell cycle arrest in human KOPN8 cells assessed as increase in accumulation of cells at S phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623671	Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623666	Intrinsic clearance in human microsomes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623681	Induction of apoptosis in human KOPN8 cells assessed as decrease in cell viability at 5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric analysis	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623670	Apparent permeability of compound form basolateral to apical side in human Caco2 cells	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1623662	Antiproliferative activity against human BJ assessed as cell viability after 72 hrs by CellTiter-Glo assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (57.14)	24.3611
2020's	3 (42.86)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
albendazole [no description available]	2.21	1	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.21	1	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.21	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.21	1	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester [no description available]	2.21	1	piperidines
staurosporine [no description available]	2.21	1	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
vincaleukoblastine [no description available]	2.21	1	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	2.21	1	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic

Condition	Relationship Strength	Studies
Leucocythaemia [description not available]	2.21	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.21	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

stf-118804

Cross-References

Synonyms (33)

Research Excerpts

Bioavailability

Protein Targets (6)

Potency Measurements

Biological Processes (45)

Molecular Functions (18)

Ceullar Components (22)

Bioassays (48)

Research

Studies (7)

Market Indicators

Research Demand Index: 17.61

Study Types

stf-118804

Cross-References

Synonyms (33)

Research Excerpts

Bioavailability

Protein Targets (6)

Potency Measurements

Biological Processes (45)

Molecular Functions (18)

Ceullar Components (22)

Bioassays (48)

Research

Studies (7)

Market Indicators

Research Demand Index: 17.61

Study Types

Related Drugs (8)

Related Conditions (5)